Role of Heparin in the Antithrombotic Treatment of Valvulopathies

Guy Hanania
Service de Cardiologie, Hôpital Robert-Ballanger, Aulnay-sous-Bois, France

 

Heparin is indicated to replace warfarin in patients with valve disease requiring antithrombotic treatment. Its use is thus necessary for short periods during which warfarin is contraindicated, but the thromboembolic risk persists. These circumstances, which are common in patients with mechanical prostheses, include: hemorrhagic risk or event complicating an existing thromboembolic risk (heart or extracardiac surgery, severe hemorrhage, end of pregnancy); when an unstable situation develops and imposes the rapid diminution or interruption of anticoagulants (stroke, infectious endocarditis); when immediate efficacy is required, rather than the delayed action of warfarin (onset of atrial fibrillation); and when warfarin is contraindicated (early pregnancy). Regardless of whether

unfractionated or low molecular-weight heparin (LMWH) is used, therapeutic doses must be prescribed: continuously perfused intravenous and subcutaneous injections (t.i.d.) with repeated biological monitoring for the former, or subcutaneous injections (b.i.d.) with initial biological controls preferred and repeated in elderly subjects or those suffering from renal insufficiency. International guidelines have specified the respective roles of heparin in general, and each preparation individually with an ever-increasing use of LMWH, the efficacy of which has been proven in the majority of common thromboembolic pathologies and in pregnant women.
The Journal of Heart Valve Disease 2004;13:339-343
 
Untitled Document
Registered Users
Click here to view the file in pdf format or click here to logout from the site

Subscribers

You must be a subscriber and registered with the site to view these files. If you are a subscriber but have not yet registered with the site please click here.


Not yet subscribed?
Click here to subscribe using our simple online system